20/20 BIOLABS INC
AIDX · NASDAQ
Updated at 2026-10-14 09:34:49
- Today's High
- $0.37
- Today’s Low
- $0.34
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.38
- Previous Close
- $0.36
- Volume
- 181.97K
- Market Cap
- $4.67M
- P/E Ratio
- --
- EPS
- $-0.93
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Health Care
- Sub-industry
- MEDICAL DEVICES
- Headquarters
- 15810 GAITHER ROAD, GAITHERSBURG, MD, UNITED STATES, 20877
- Country
- US
- Listing Date
- 2021-09-08
- Fiscal Year End
- December
- Shares Outstanding
- 12.25M
- CIK
- --
- Website
- 2020gene.com
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Financial Metrics
Revenue
2026-06-30
$730.57K
2026-03-31
$353.37K
2025-12-31
$538.27K
2025-09-30
$417.97K
Operating Expenses
2026-06-30
$1.54M
2026-03-31
$1.5M
2025-12-31
$1.04M
2025-09-30
$945.23K
Net Income
2026-06-30
-$1.5M
2026-03-31
-$2.17M
2025-12-31
-$1.3M
2025-09-30
-$825.53K
Net Profit Margin
2026-06-30
-206.18%
2026-03-31
-615.44%
2025-12-31
-242.95%
2025-09-30
-197.5%
Earnings Per Share
2026-06-30
$-0.26
2026-03-31
$-0.28
2025-12-31
$-0.12
2025-09-30
--
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$1.22M
2026-03-31
-$1.89M
2025-12-31
-$894.97K
2025-09-30
-$780.94K
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $730.57K | $353.37K | $538.27K | $417.97K |
| Operating Expenses | $1.54M | $1.5M | $1.04M | $945.23K |
| Net Income | -$1.5M | -$2.17M | -$1.3M | -$825.53K |
| Net Profit Margin | -206.18% | -615.44% | -242.95% | -197.5% |
| Earnings Per Share | $-0.26 | $-0.28 | $-0.12 | -- |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$1.22M | -$1.89M | -$894.97K | -$780.94K |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.